A double-blind, placebo-controlled Phase IIa study of C21 on idiopathic pulmonary fibrosis (IPF) patients
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2018
At a glance
- Drugs C-21 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- 11 Jul 2018 New trial record
- 03 Jul 2018 According to a Vicore Pharma media release, the company has received approval for this trial to be initiated in 2020.
- 18 Apr 2018 According to a Vicore Pharma media release, this trial will be conducted with clinical research partners at different hospitals and with PAREXEL. Dr Joanne Porter at the University College of London (UCL) is the principle investigator for the study.